Valid Insight (part of the Bioscript Group)

📊 Exploring the Psychology of Payer Decision-Making at #ISPOREurope2024 📊 Today, Maria Elisa Capobianco presented our poster on Psychological Aspects of Payer Decision-Making in Healthcare, sparking great discussions around the influence of cognitive, emotional, and behavioural factors on payer decisions. Key takeaway? The framing of evidence and value communication plays a crucial role in driving impactful payer engagement. Our expertise lies in structuring value communication strategies that resonate with payers and key decision-makers, ensuring evidence is both compelling and actionable. ✨ Curious to learn more about our findings and how we can support your access strategies? Email us at discover@bioscriptgroup.com 📖 Read the poster abstract here: https://lnkd.in/eqd2Cex2 #ISPOREurope2024 #HEOR #MarketAccess #ValueCommunication #PayerEngagement

🌐 Welcome to ISPOR Europe 2024! 🌐 We’re thrilled to be here in Barcelona! Visit Valid Insight (part of the Bioscript Group) at Booth 928 and connect with our team of experts, including Gerdi Strydom, Lucy Nelson, and Maria Elisa Capobianco. Let’s discuss how our HEOR and access capabilities can support your market access strategies. We are excited to kick off this event and have conversations with customers, prospects, and partners alike! 📩 discover@bioscriptgroup.com #ISPOREurope #MarketAccess #HTA #HEOR

🌐 ISPOR Europe 2024 is almost here! Meet the Valid Insight team, part of the BioScript Group, in Barcelona from November 17-20! 🌐 Find Gerdi Strydom, Patricia Buchholz, Lucy Nelson, and Maria Elisa Capobianco at Booth 928 to learn how our HEOR and market access expertise can empower your therapy’s journey. ✉️ Schedule a meeting today at discover@bioscriptgroup.com #ISPOREurope2024 #HEOR #MarketAccess #HTA 

🌐 Meet Valid Insight (part of the Bioscript Group) at ISPOR Europe 2024 in Barcelona! 🌐 Our team, including Gerdi Strydom, Patricia Buchholz, Lucy Nelson, and Maria Elisa Capobianco, will be at Booth 928 from 17-20 November. We invite you to connect with us and explore how our tailored HEOR, market access, and value communication strategies can help optimize access for your therapies. Email us at discover@bioscriptgroup.com to schedule a meeting in advance! #ISPOREurope2024 #HEOR #MarketAccess #HTA #EvidenceGeneration

Just 2 Days Until the World Orphan Drug Congress Europe 2024! Our team from Valid Insight (part of the Bioscript Group) is excited to meet you at Booth 111! Let's connect and discuss how we can support your goals in rare diseases and orphan drugs. To schedule a meeting, reach out to us at discover@bioscriptgroup.com We look forward to seeing you there! #WorldOrphanDrugCongress #OrphanDrugs #RareDiseases #PatientAdvocacy #MarketAccess 

🌟 Leveraging Real-World Evidence to Address HTA Challenges in Cell and Gene Therapy 🌟 In today’s rapidly evolving healthcare landscape, cell and gene therapies (CGTs) are transforming the treatment of rare diseases. Yet, Health Technology Assessment (HTA) bodies continue to raise concerns over long-term data gaps and the assumption of lasting therapeutic benefits. How can pharmaceutical companies overcome these challenges and secure market access? The solution lies in Real-World Evidence (RWE). 🔹 Utilize patient registries, electronic health records, and claims data to design trials that ensure every patient receives the necessary treatment while demonstrating real therapeutic value. 🔹 Bridge the gap between clinical trials and real-world care by showing long-term safety and efficacy, especially for potentially curative therapies. 🔹 Strengthen product claims by focusing on patient-reported outcomes (PROs) and addressing real-world challenges throughout the drug development lifecycle. At Valid Insight, we specialize in helping CGT developers navigate these challenges. As part of the Bioscript Group, we offer: ✅ Expertise across the entire lifecycle – from evidence generation to developing value communication materials that resonate with payers and regulators. ✅ Training and support to ensure effective negotiation for market access, bringing your innovative therapies to patients efficiently. Want to learn how to overcome HTA barriers and bring breakthrough therapies to patients? Meet us at Booth 111, or email discover@bioscriptgroup.com to arrange a meeting! #CellAndGeneTherapy #HTA #RealWorldEvidence #MarketAccess #PatientCentric

We are thrilled to share that our Managing Director, Gerdi Strydom, was a special guest on the Market Access Podcast (MAP) hosted by Stefan Dr. Walzer from MArS Market Access & Pricing Strategy GmbH. 🎙️ In this insightful episode, Gerdi dives into the growing importance of integrating #ESG (Environmental, Social, and Governance) principles into #HealthTechnologyAssessments (HTAs) and discusses how sustainability is reshaping healthcare, industry strategy, and payor decision-making across Europe. 🌿 Tune in to hear about: 🔹 The role of carbon footprint and environmental impact in shaping policy and healthcare decision-making. 🔹 How some are leading the way with low-carbon pharmaceuticals, including healthcare systems and the pharmaceutical industry. 🔹 The future of market access and how global collaboration drives healthcare sustainability. 🎧 Listen to the full episode here: https://lnkd.in/dyTZ3yQb Join the conversation and stay ahead of the trends in market access and sustainability! #HealthcareInnovation #Sustainability #HTA #ESG #MarketAccess

🌍 Join us at the World Orphan Drug Congress 2024! 🌍 We’re excited to announce that Gerdi Strydom, Stephen H., Sarah Holland, and Inês Rodrigues de Oliveira will be representing Valid Insight (part of the Bioscript Group) at the World Orphan Drug Congress in Barcelona, 22-25 October. Come visit us at Booth 111 or schedule a meeting in advance by contacting us at discover@bioscriptgroup.com. Let’s discuss how we can help you navigate the challenges of market access, rare diseases, and orphan drugs. #WorldOrphanDrugCongress, #OrphanDrugs, #RareDisease, #PatientAdvocacy, #MarketAccess

In 2023, we proudly announced that Bioscript Group had earned a silver medal in the EcoVadis sustainability performance assessment, showcasing our unwavering commitment to responsible business practices. 🌟 Reflecting our continuous endeavour to become more sustainable, we are thrilled to share that we have retained the silver medal in 2024, while significantly boosting our overall EcoVadis score from 60 to an impressive 71/100! 🙌 We have also soared from the 77th to the 93rd percentile, and from the top 25% of companies to the top 15%! 📈 At Bioscript Group, we recognise the urgent need to address climate change and are committed to operating sustainably and responsibly. 🌍 If you'd like to dive deeper into our holistic approach to sustainability, be sure to check out our 2024 ESG report here: https://loom.ly/YazZKJ4 #Sustainability #ESG #ClimateAction #Pharma #BioscriptGroup

On Saturday, we celebrated #WorldRetinaDay at the EURETINA Congress, reaffirming our continuing commitment to advancing access to sight-saving therapies globally. At Valid Insight, part of the Bioscript Group, we leverage our expertise in ophthalmology to navigate the unique market access challenges of retinal diseases worldwide. Together, let's raise awareness, champion research, and strive for a world where everyone can see a brighter future. #WorldRetinaDay #Ophthalmology #EURETINA